BioSpace News Archive

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment in its Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. With this milestone, the data readout for the Day 28 immunogenicity endpoint remains on target for Q4 2020. The clinical trial has enrolled 42 evaluable healthy subjects to receive intranasally administered NasoShield or

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, will participate in a fireside chat at the 2020 Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 11 at 10:20 a.m. ET. A live audio webcast of the presentation will be available here and on the Company’s website at www.arvina

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Dr. David Sans as Director, Corporate Development to be based in New York City. Dr. Sans will be responsible for planning and facilitation of XORTX corporate goals. Dr. Sans is an experienced pharmaceutical executive

--Expands AI/ML Capabilities and Gains Exclusive Rights to Leading Suite of Cheminformatics Technologies-- --Conifer Point’s Technologies Enable Expansion of Lodo’s P4 Platform™ to Include Therapeutic Target-Based De Novo Drug Discovery-- --Represents Major Advance in Lodo’s Reinvention of Natural Product Drug Discovery-- --Lodo to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference--

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman , Nevro’s Chairman, CEO and President, will present at the Canaccord Genuity 40 th Annual Virtual Growth Conference on August 13, 2020 , be

AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 34,500 shares of the company’s common stock to three new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.

On track to report interim efficacy and safety results from TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA) in 4Q20 - Enrollment expected to advance to combination treatment of SRK-181 and an approved anti-PD-(L)1 therapy in Part A of DRAGON Phase 1 clinical trial in 3Q20; update on dose escalation expected in 4Q20 - Appointed Tony Kingsley as President and CEO and Ted Myles as CFO and He

Nura Bio Inc., a biopharma company created to discover and develop life-changing neuroprotective drugs, today announced the publication of “Structural and Mechanistic Regulation of the Prodegenerative NAD Hydrolase SARM1” in CELL REPORTS.

Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in three upcoming virtual investor conferences. Presentation Details: Event: BTIG Virtual Biotechnology Conference Date: Monday, August 10, 2020 Time: 9

Cybin Corp. (“Cybin” or the “Company”), Canada’s leading-edge mushroom life sciences company, is proud to applaud the efforts of TheraPsil, a non-profit coalition that advocates for legal, Special Access Programme (SAP) access to psilocybin therapy for palliative care of Canadians.